Healthcare -
Biotechnology - NASDAQ - US
$ 0.0606
-8.04 %
$ 2.56 M
Market Cap
-0.05
P/E
1. INTRINSIC VALUE
Balance Sheet
Spruce Biosciences, Inc.
| Current Assets | 44.2 M |
| Cash & Short-Term Investments | 38.8 M |
| Receivables | 0 |
| Other Current Assets | 5.45 M |
| Non-Current Assets | 1 M |
| Long-Term Investments | 0 |
| PP&E | 934 K |
| Other Non-Current Assets | 69 K |
| Current Liabilities | 15.2 M |
| Accounts Payable | 1.3 M |
| Short-Term Debt | 1.9 M |
| Other Current Liabilities | 12 M |
| Non-Current Liabilities | 1.14 M |
| Long-Term Debt | 860 K |
| Other Non-Current Liabilities | 282 K |
EFFICIENCY
Earnings Waterfall
Spruce Biosciences, Inc.
| Revenue | 4.91 M |
| Cost Of Revenue | 0 |
| Gross Profit | 4.91 M |
| Operating Expenses | 61.1 M |
| Operating Income | -56.2 M |
| Other Expenses | -3.12 M |
| Net Income | -53 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Spruce Biosciences, Inc.
| Net Income | -53 M |
| Depreciation & Amortization | 46 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 5.35 M |
| Change in Working Capital | -8.57 M |
| Others | -6.53 M |
| Free Cash Flow | -56 M |
Wall Street Analysts Price Targets
Spruce Biosciences, Inc.
SPRB has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
SPRB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Spruce Biosciences, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates. “With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients a.
businesswire.com
- 1 month ago
Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)
Spruce Biosciences, Inc. (NASDAQ:SPRB ) Corporate Update Conference Call April 15, 2025 8:30 AM ET Company Participants Samir Gharib - President and CFO Javier Szwarcberg - CEO Kirk Ways - Chief Medical Officer Conference Call Participants Joe Schwartz - Leerink Partners Jon Wolleben - JMP Leland Gershell - Oppenheimer Ram Selvaraju - H.C. Wainwright Operator Welcome to the Spruce Biosciences Investor Call [Operator Instructions].
seekingalpha.com
- 2 months ago
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). “This is truly a transformative moment for Spruce as we focus ou.
businesswire.com
- 2 months ago
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 6 months ago
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
On Tuesday, Spruce Biosciences, Inc. SPRB revealed topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH.
benzinga.com
- 6 months ago
Spruce Biosciences to wind down investment for genetic disorder drug
Spruce Biosciences said on Tuesday it will wind down investments for its genetic disorder drug after it failed to meet the main goal in a mid-stage study.
reuters.com
- 6 months ago
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH. “We are very grateful to all the patients, families, investigators, and the e.
businesswire.com
- 6 months ago
Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates
Spruce Biosciences, Inc. (SPRB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.30 per share a year ago.
zacks.com
- 7 months ago
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 7 months ago
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 7 months ago
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Take Part
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 7 months ago
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 3:30 p.m. ET. Interested parties can access the live webca.
businesswire.com
- 7 months ago
8. Profile
Summary
Spruce Biosciences, Inc. SPRB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 2.56 M
Dividend Yield
0.00%
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Contact
2001 Junipero Serra Boulevard, Daly City, CA, 94014
https://www.sprucebiosciences.com
IPO
Date
Oct. 9, 2020
Employees
20
Officers
Mr. Samir M. Gharib CPA, M.B.A.
President & Chief Financial Officer
Dr. Javier Szwarcberg M.D., M.P.H.
Chief Executive Officer & Director
Mr. Michael G. Grey
Executive Chairman
Dr. Kirk Ways M.D., Ph.D.
Chief Medical Officer & Director